Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a treatment option for relapsed anaplastic large cell lymphoma (ALCL) in children, but reports on its efficacy in this disease are still limited. We analyzed data concerning 34 patients under 18 years of age prospectively registered in the French SFGM-TC database, who had undergone an allo-SCT for the treatment of ALK+ ALCL between 1993 and 2011. At transplant, 28 patients (82.4%) were in CR, whereas 6 exhibited detectable disease. Conditioning regimens were mostly myelo-ablative (n = 31). With a median follow-up of 6 years, 5-year overall and event-free survival rates were 70% (SE = 8%) and 58% (SE = 9%), respectively. The 5-year cumulative incidence of relapse and treatment-related mortality was 18% (SE = 7%) and 24% (SE = 8%), respectively. Six patients had relapsed (median time, 141 days (35-235)). A durable CR had been obtained in 4/6 patients after injection of donor lymphocytes (n = 1) or vinblastine-corticosteroid therapy (n = 3). Ten patients had died, eight due to transplant toxicity and two due to progressive disease. Allo-SCT is an efficient treatment for pediatric patients with high-risk relapsed ALK+ ALCL. However, the overall morbidity of allo-SCT raises questions about its place, given the efficacy of targeted agents currently under development in this disease. 1 Treatments based on multiagent chemotherapy over a short period (o 6 months) are successful in most patients.
INTRODUCTION
Anaplastic large cell lymphomas (ALCL) account for 10-15% of childhood non-Hodgkin lymphomas. 1 Treatments based on multiagent chemotherapy over a short period (o 6 months) are successful in most patients. 2 However, relapses occur in 25-30% of cases, mostly within 6 months after treatment. 3 CR can once again be achieved at relapse in most patients with a wide variety of chemotherapy regimens. Thus, the 2-year overall survival rate in children treated for an ALCL exceeds 85% in the most recent reports and has attained 94% in the ALCL99 international trial. 2 In most patients, the treatment strategy for relapse comprises autologous or allogeneic hematopoietic stem cell transplantation (allo-SCT) after a CR. The feasibility and efficacy of allo-SCT with good engraftment, acceptable toxicity and event-free survival rate ranging from 45 to 75% has been demonstrated in small series and case reports published so far. [4] [5] [6] [7] [8] [9] Several risk factors have previously been associated with an unfavorable outcome in retrospective series of patients with relapsed ALCL. Relapses occurring within 12 months of the initial diagnosis and especially relapses occurring during therapy have been associated with lower survival. 3, 10 In the report by the BFM group, bone marrow or central nervous system involvement (CNS) at relapse and CD3 expression on the surface of tumor cells were found to be associated with a worse prognosis. 10 To date, allo-SCT is usually recommended in patients with a progression/relapse associated with poor prognostic factors. To better assess the impact of allo-SCT in pediatric ALCL, we report on a series of 34 children and adolescents who had undergone allogeneic transplantation for relapsed or refractory ALCL.
MATERIALS AND METHODS

Study design and eligibility criteria
Patients were identified through the Société Française de Greffe de Moëlle et de Thérapie Cellulaire (SFGM-TC) database. This database prospectively registers information concerning patients who undergo stem cell transplantation in France. Clinical data and information concerning the diagnosis and relapse were collected prospectively through the Société Française des Cancers de l'Enfant (SFCE) databases for childhood ALCL. Written informed consent for data registration was obtained from each patient or parent and donor.
All 34 patients under 18 years of age, who had undergone an allo-SCT between 1993 and 2011 for relapsed/progressive ALK+ ALCL, were included in this study. The diagnosis of ALCL, at initial onset and at the first relapse, was based on morphologic and immunophenotypic criteria. 
Chemotherapy regimen
Front-line treatment was mainly based on specific protocols for ALCL (HM97 n = 4 and ALCL99 n = 27). 2, 12 Three patients had initially been treated in B-cell lymphoma protocols for various reasons (CNS involvement, misdiagnosis with B-cell lymphoma, leukemic form). The treatment of relapse or progression was not standardised until 2004, when the ALCL-Relapse protocol was opened (NCT00317408).
Transplant procedure
The decisions concerning the conditioning regimen and prophylaxis against GVHD had been left to the discretion of the local allo-SCT boards. A matched sibling donor had been selected when available. Otherwise, another stem cell source, including a matched or mismatched (49/10) unrelated donor, umbilical cord blood or double umbilical cord blood, had been used by the local physicians.
End points
Acute and chronic GVHD had been graded according to previously published criteria. Time to neutrophil engraftment was defined as the first of three consecutive days during which the ANC exceeded 0.5 × 10 9 /L. Time to platelet engraftment was defined as the first of 3 days with a platelet count 4 20 × 10 9 /L without a platelet transfusion over a 5-day period. Patient-donor chimerism in unsorted peripheral blood had been assessed at day 100. Full donor chimerism was defined as the presence of 495% of donor cells using FISH to detect X and Y chromosomes for recipients of sex-mismatched transplants and PCR-based analysis of polymorphic microsatellite regions for recipients of sex-matched transplants.
Acute GVHD had been evaluated according to Seattle standard criteria. PFS was defined as the time between the date of allo-SCT and the date of progression, a subsequent relapse or death, whatever the cause. Overall survival was defined as the time between the date of allo-SCT and the date of death, whatever the cause.
Statistical considerations
PFS and overall survival were estimated using the Kaplan-Meier method. The cumulative incidences of relapse, transplant-related mortality (TRM) and GVHD were estimated using the Kalbfleisch and Prentice's method for competing events. 13 Treatment-related death was considered as a competing event of relapse, death due to disease progression as a competing event of treatment-related death, and death due to whatever the cause as a competing event of GVHD. The evolution of the risk of TRM before and after 2004 was tested using the Fine and Gray's regression method. 14 We also studied prognostic factors for the risk of relapse using the same approach, including the GVHD as a time-dependent variable.
The analyses were performed using SAS 9.1 software and the cmprsk R-package.
RESULTS
Patient characteristics before allo-SCT
The study spans more than 19 years and 10 patients had undergone allo-SCT before 2004 (29%). The main patient characteristics at diagnosis are shown in Table 1 . The NPM1-ALK fusion transcript had been detected in bone marrow at relapse in 9 of the 10 patients analyzed.
In 29 patients, the indications for the allogeneic transplant procedure were based on the following criteria: progression during first-line therapy (n = 4, ALCL99), a leukemic form that had not achieved a CR after first-line therapy (n = 2), the first relapse associated with at least one risk factor (n = 14) such as CD3 positivity (n = 9), a leukemic form (n = 1), an NPM1-ALK fusion transcript detected in bone marrow (n = 8) and/or central nervous system involvement (n = 1), or a subsequent relapse (second relapse, n = 6; third relapse, n = 3). In five patients, allo-SCT had been performed after a first relapse with none of the abovementioned risk factors. Most patients who had undergone allo-SCT after a first relapse had been treated after 2004 (16/19 patients). For the 19 patients treated with allo-SCT after a first relapse, the median interval between the diagnosis and the first relapse was 7.9 months (range, 5.3-14.0).
The chemotherapy regimens administered before allo-SCT are detailed in Table 2 . Of the 19 patients treated with allo-SCT after a first relapse, 14 had received intensive courses of ICM (Ifosfamide, Carboplatine Mitoxantrone), ICI (Idarubicine, Carboplatine, Ifosfamide), CC (Aracytine, Etoposide, Vindesine) and CVA (Aracytine, Vinblastine, Lomustine) chemotherapy, as previously described, two had received weekly vinblastine and three miscellaneous B-cell lymphoma-based chemotherapy. 3, 10 Among the 15 patients treated with allo-SCT for a second or a further relapse, six had undergone autologous transplantation for a previous relapse before allo-SCT with a median interval of 13.8 months (range, 5.3-28.6) between the two procedures.
A CR had been achieved before allo-SCT in 3/4 patients who had undergone allo-SCT because of progression during front-line chemotherapy, in 1/2 patients who had a leukemic form with detectable disease at the end of initial therapy and in 25/28 patients treated with allo-SCT at relapse. Allo-SCT in childhood refractory or relapsed ALCL M Strullu et al
Allo-SCT characteristics
The median age at allo-SCT was 9.3 years (6.1-12.2). At the time of the transplant, six patients had detectable disease, including one patient who had relapsed during the conditioning regimen, and 28 patients were in CR (CR1 n = 4, CR2 n = 16, CR3 n = 5, CR4 n = 3). Thirty-one patients had undergone myelo-ablative conditioning (MAC), including a 12 Gy dose of TBI delivered to 26 patients. Three patients had undergone reduced-intensity conditioning (RIC). Most donors were unrelated (n = 22), including 9 HLAmatched donors, 3 HLA-mismatched donors and 10 cord blood units ( Table 3 ). The transplant had been performed with bone marrow in 16 patients and with PBSCs in 8.
Engraftment
Three patients had failed to engraft despite a sufficient number of CD34+ cells infused from three mismatched unrelated donors. For the other 31 patients, the median times to neutrophil and platelet engraftment were 22 days (9-44) and 26.5 days (8-406), respectively. Full-donor chimerism had been achieved in 30 patients, whereas one patient had died before assessment.
Toxicity Twenty-five patients had developed acute GVHD, including grade 3-4 acute GVHD in five cases. The 100-day cumulative incidence of acute GVHD was 73.5% (SE = 7.9%). Five patients harbored chronic GVHD. Eight children had died of toxicity secondary to pulmonary infection (n = 1), chronic GVHD (n = 3), heart failure (n = 1), multi-organ failure (n = 2) and of an undetermined reason (n = 1). The 5-year cumulative incidence of TRM was 24.1% (SE = 7.6%). Among the eight patients who had died of toxicity, two had previously undergone an autologous transplant and three had experienced two or more relapses before allo-SCT. The conditioning regimens were mainly myelo-ablative (6/8 patients) and included TBI at a dose of 12 Gy in five patients. The risk of TRM was higher in patients transplanted before 2004 (3/10) than in those treated in 2004 or later (3/24) (Hazard ratio of TRM = 5.2, 95% confidence interval, 1.2-21.9, P-value = 0.02).
Disease outcome and survival Six patients had relapsed after a median period of 141 days (range, 35-235) after the transplant. Among them, three had not achieved a CR at transplant and four harboured acute GVHD. We found a non-significant trend toward a reduced risk of relapse in patients who had experienced acute GVHD compared with those who had not (HR = 0.26, 95%CI, 0.05-1.46, P-value = 0.13). Among the six patients who had experienced a relapse, four patients are still alive in CR with a follow-up of 12, 6, 4 and 2 years, respectively: three after vinblastine-corticosteroid therapy and one after donor lymphocyte injections. Overall, only 2/34 patients had died of tumor progression. With a median follow-up of 6.0 years (range, 1.1-12.5) after allo-SCT, the Kaplan-Meier estimates for the 5-year overall survival and PFS rates were, respectively, 70.0% (SE = 8.0%) and 58.1% (SE = 8.6%) for the whole series (Figure 1 ). The 5-year cumulative incidence of relapse was 17.6% (SE = 6.7%) (Figure 2) . A comprehensive prognostic factor study was not feasible due to the small number of patients and of events (eight TRM and six relapses, respectively). For the 19 patients treated with allo-SCT after a first relapse, the 5-year overall survival and PFS rates were 94.7% (SE = 5.1%) and 73.7% (SE = 10.1%), respectively. Of the four patients who had experienced progression during front-line therapy, three had died of toxicity while one is still in CR after 4 years of follow-up. Of the six patients transplanted with detectable disease, three are alive including the patient whose disease had progressed during the conditioning regimen. Of the three patients who had undergone an RIC conditioning regimen, one is alive free of disease at 6 years.
DISCUSSION
This study describes the French experience with allogeneic SCT for the treatment of children and adolescents with relapsed or Figure 1 . Overall (OS) and progression-free survival (PFS). Allo-SCT in childhood refractory or relapsed ALCL M Strullu et al refractory ALCL over an 18-year period. Our data confirm the efficacy of this procedure with a 5-year PFS of 58% and a 5-year cumulative relapse risk of 18% in this population of patients with high-risk relapsed/progressive ALCL. In addition, we show that allo-SCT can be successful in patients with progressive disease during first-line treatment. We also report CRs in patients with detectable disease at the time of transplantation including one patient whose disease progressed during the conditioning regimen. Our study did not allow us to identify prognostic factors for the risk of relapse after HSCT, due to the small number of patients and events, as well as potential confounding factors (supplementary Table 1 ). However, our results are consistent with those of other studies, based on smaller series of patients with refractory or relapsed ALCL ( Table 4 ) that reported EFS rates between 46 and 75%. [4] [5] [6] [7] [8] [9] 15 In the three largest series, relapse rates were relatively low ranging from 10 to 28%, whereas toxicity-related mortality accounted for a large proportion of the events. Owing to the small numbers of patients included in each of these reports, no prognostic factor was identified but the authors pointed out the efficiency of this treatment in heavily pre-treated patients and in patients who had previously experienced disease progression under first-line chemotherapy.
Given the accumulated data suggesting the role of the immune system in the physiopathology of ALCL, the use of allo-SCT associated with a potential GvL effect is quite logical. [16] [17] [18] [19] [20] Our study was not sufficiently powered to detect this association. The graft versus ALCL effect is also supported by the observation that disease control was obtained in the present series in a girl who had relapsed after a transplant with donor lymphocyte injections, a procedure previously reported to have been efficient for the treatment of post transplant relapses in a few cases of adult aggressive T-cell lymphoma. 15, 16 Although the efficacy of this procedure in relapsed/refractory ALCL has been clearly shown in our series as in most series in the literature, the benefit associated with the reduction in treatment failure has to be weighed against the increased risk of mortality and long-term morbidity due to allo-SCT. In our series, as in most series in the literature, toxicity was the main cause of death with a 5-year TRM rate estimated at 24% in the whole series. The reduced TRM rate in recent years is reassuring, but may reflect not only the improvement of transplant procedures and supportive care, but also changes in patient selection, with the indication of allo-SCT earlier during the course of the disease over the last decade. 21, 22 A wider use of RIC could also reduce morbidity and TRM. In our series, the great majority of patients had received MAC with a 12-Gy dose of TBI in most cases. These conditioning regimens are considered the benchmark in pediatric allo-SCT, as they offer the best control of malignancy with manageable toxicity in patients in good condition. Conversely, the experience of RIC is rather limited in the pediatric population but its tolerance and efficiency have been demonstrated in recent years in patients who were not eligible for MAC. RIC regimens would reduce short-and even longterm side effects. 23, 24 The efficacy of this procedure has been achieved in 1/3 case in the present series as well as in several cases in literature 4, 25 and especially in the recently published series from Japan in which 3/4 patients treated with a RIC regimen survived with no further relapse. 9 Performing an allograft at the first relapse may alleviate the toxicity of the procedure. However, allo-SCT may not be necessary for long-term disease control in all patients because a large number of patients with recurrent ALCL remain sensitive to chemotherapy. This in fact leads to 3-year survival rates of over 55% in relapsed ALCL in several series in the literature including a substantial proportion of patients treated without allo-SCT. 3, 7, 10 Owing to the rate of short-and long-term morbidity associated with allo-SCT, this procedure should be applied exclusively in patients who cannot be cured with other therapeutic options.
We acknowledge the fact that the relative efficacy of this strategy compared with other possible approaches could not be estimated due to the design of this study. Several other options have been proposed for the treatment of relapsed ALCL including autologous SCT after reinduction with conventional chemotherapy, weekly vinblastine and more recently targeted therapy such as brentuximab vedotin and ALK inhibitors. [26] [27] [28] [29] [30] Several series exploring the role of autologous SCT suggest that despite a lower rate of TRM, this procedure is less efficient than allo-SCT with 5-year EFS rates of between 35 and 59% and relapse rates exceeding 40% in the largest series published to date (Table 4) . The efficacy of long-lasting chemotherapy with low-dose chemotherapy such as vinblastine or etoposide has been reported in several patients either for front-line treatment or for the treatment of relapse. 3, 10, 31, 32 Interestingly, three of the six patients who had relapsed after allo-SCT in our series subsequently achieved a Abbreviations: allo-SCT = allogeneic stem cell transplantation; EFS = event-free survival; OS = overall survival; NA = not available.
a Three-year EFS.
Allo-SCT in childhood refractory or relapsed ALCL M Strullu et al prolonged CR with vinblastine. As most patients can be rescued after a further relapse, it seems logical to propose vinblastine for the first relapse except for patients with progression during frontline therapy who are at high risk of failure with such treatment. Recently, targeted drugs such as brentuximab vedotin or ALK inhibitors have been developed and have yielded remarkable response rates with limited toxicities. 29, 30, [33] [34] [35] [36] However, the follow-up of the patients treated with these new targeted therapies is still short and we still do not know whether they will be able to lead to complete cure of ALCL or if they will have to be considered as a bridge to induce complete response before allo-SCT.
Thus, the indication of allo-SCT will have to be discussed for each patient who achieves a CR with brentuximab vedotin or crizotinib, taking into account the uncertainty concerning the risks of a prolonged treatment with brentuximab vedotin or ALK inhibitors vs the well known morbidity of allo-SCT.
While progression during front-line treatment has been shown by all authors to be associated with very low survival, the prognostic impact of factors, such as the presence of the NPM-ALK fusion transcript in blood and/or bone marrow and low-Ab titers against the ALK Ag, shown to have a prognostic impact at diagnosis has not yet been assessed in relapsed patients. They might lead to the identification of patients at high risk of failure with conventional approaches. 37, 38 Altogether, despite its obvious limitations due to the small number of patients and the heterogeneity of the indications, this report shows that allo-SCT is an efficient treatment for the management of pediatric patients with high-risk relapsed or refractory ALK+ ALCL. Defining the role of this procedure in the treatment of relapsed ALCL will require a better knowledge of prognostic factors after relapse and an evaluation of the long-term outcome of patients treated with vinblastine and targeted therapy, such as brentuximab vedotin and ALK inhibitors.
